The ADCK1 Knockout HT29 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human colorectal adenocarcinoma cell line HT29. This product provides a loss-of-function model for the ADCK1 gene, which encodes a mitochondrial atypical kinase. The polyclonal population contains a heterogeneous mixture of edited alleles, enabling robust functional studies without single-cell cloning artifacts. ADCK1 disruption is achieved through CRISPR/Cas9-mediated gene targeting, making these cells suitable for investigating ADCK1-dependent mitochondrial biology and cancer cell phenotypes.
The HT29 cell line was isolated from a primary colon adenocarcinoma of a 44-year-old female patient and has become a widely accepted model for colorectal cancer research. These epithelial tumor cells retain key oncogenic signaling pathways and metabolic characteristics of colorectal adenocarcinoma, making them an appropriate host for studying mitochondrial kinase function in cancer. HT29 cells are extensively employed in drug screening, metabolism assays, and tumor biology investigations.
ADCK1 functions as a mitochondrial atypical kinase essential for coenzyme Q biosynthesis and electron transport chain activity. It partners with the COQ protein complex, including COQ3, COQ5, and COQ7, to produce coenzyme Q, which shuttles electrons between complexes I/II and III. ADCK1 activity promotes mitochondrial respiration and ATP production through interaction with ATP synthase subunits. Upstream, ADCK1 expression is positively regulated by c-Myc and mTORC1 signaling, linking nutrient sensing to mitochondrial output. Downstream, loss of ADCK1 disrupts electron transport chain complexes I?CIV function, leading to reduced coenzyme Q levels, altered reactive oxygen species (ROS) generation, and impaired ATP synthesis. In addition, ADCK1 influences AMPK?? signaling, which coordinates cellular energy status with metabolic responses. Thus, ADCK1 integrates oncogenic and metabolic cues to sustain mitochondrial fitness and cancer cell proliferation.
In HT29 colorectal cancer cells, ADCK1 upregulation enhances mitochondrial respiration, supports proliferation, and facilitates migration, consistent with its role in tumorigenesis. The ADCK1 Knockout HT29 Polyclonal Cells therefore provide a physiologically relevant system to dissect how mitochondrial kinase dysfunction impacts colorectal cancer metabolism. By eliminating ADCK1 expression in this epithelial tumor background, researchers can examine the dependency of cancer cells on coenzyme Q biosynthesis and electron transport chain integrity. This model is particularly valuable for exploring crosstalk between mTORC1, c-Myc, and mitochondrial bioenergetics in oncogenic signaling.
Key applications include investigating mitochondrial respiratory chain electron transport, coenzyme Q biosynthesis, and AMPK/mTORC1 signaling pathways. Researchers can employ Seahorse mitochondrial stress tests to measure oxygen consumption rate, intracellular ATP luminescence assays for energy production, and DCFDA-based detection of reactive oxygen species. ADCK1 loss can be validated by Western blot and RT-qPCR, and functional consequences assessed by MTS viability, wound-healing migration, and colony formation assays. Additionally, these knockout cells are suitable for quantifying coenzyme Q levels via HPLC. For technical inquiries and ordering information, please contact Ascent Research.
